No Data
No Data
imeik technology development (300896.SZ): As of July 10th, the number of company shareholders is 58,290.
On July 11th, Gelonhui reported that as of July 10th, 2024, imeik technology development (300896.SZ) had 58,290 shareholders on the investor interaction platform.
Swhy: The penetration rate continues to increase coupled with the rise of domestic products, bullish on the cosmetic and medical beauty sector.
The medical beauty industry will continue to benefit from a rich supply of products and maintain healthy development through industry standardization.
Imeik technology development (300896.SZ): The registration and listing license for type A botulinum toxin for injection has been accepted.
On July 3rd, Gelunhui reported that Imeik Technology Development (300896.SZ) recently received the "Acceptance Notice" (Acceptance Number: JXSS2400051) issued by the National Medical Products Administration, and learned that the company's overseas production drug registration and listing application has been accepted. The product name is type A botulinum toxin for injection. With the continuous development of the industry, the company has formed complementary advantages between different products through differentiated positioning and increased research and development efforts, meeting the needs of customers at different levels. After the launch of type A botulinum toxin for injection, it will work in tandem with the company's existing medical instruments products to provide more comprehensive medical beauty services.
As of June 28th, 2024, imeik technology development (300896.SZ) had 58,782 shareholders.
On July 1st, Gelonhui reported that as of June 28, 2024, imeik technology development (300896.SZ) had 58,782 shareholders on its investor relations platform.
Imeik technology development (300896.SZ): The Simigeptide injection project is currently in the pre-clinical research stage.
On June 21, Gelonhui reported that imeik technology development (300896.SZ) stated on the investor interaction platform that the company's Siglutech peptide injection project is currently in the preclinical research stage.
Recent 7.1% Pullback Would Hurt Imeik Technology Development Co.,Ltd. (SZSE:300896) Insiders
Key Insights Insiders appear to have a vested interest in Imeik Technology DevelopmentLtd's growth, as seen by their sizeable ownership 52% of the business is held by the top 5 shareholders Insti
No Data